ProQR Therapeutics (PRQR) Cash & Current Investments (2021 - 2024)
Historic Cash & Current Investments for ProQR Therapeutics (PRQR) over the last 4 years, with Q4 2024 value amounting to $159.7 million.
- ProQR Therapeutics' Cash & Current Investments rose 2477.45% to $159.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $159.7 million, marking a year-over-year increase of 2477.45%. This contributed to the annual value of $161.7 million for FY2024, which is 2570.42% up from last year.
- As of Q4 2024, ProQR Therapeutics' Cash & Current Investments stood at $159.7 million, which was up 2477.45% from $128.0 million recorded in Q4 2023.
- ProQR Therapeutics' 5-year Cash & Current Investments high stood at $219.1 million for Q4 2021, and its period low was $91.5 million during Q1 2021.
- Moreover, its 4-year median value for Cash & Current Investments was $149.8 million (2023), whereas its average is $150.5 million.
- Examining YoY changes over the last 5 years, ProQR Therapeutics' Cash & Current Investments showed a top increase of 11478.21% in 2022 and a maximum decrease of 5527.8% in 2022.
- ProQR Therapeutics' Cash & Current Investments (Quarter) stood at $219.1 million in 2021, then crashed by 55.28% to $98.0 million in 2022, then surged by 30.59% to $128.0 million in 2023, then grew by 24.77% to $159.7 million in 2024.
- Its Cash & Current Investments was $159.7 million in Q4 2024, compared to $128.0 million in Q4 2023 and $131.5 million in Q3 2023.